ADC Therapeutics (ADCT)
(Real Time Quote from BATS)
$2.61 USD
-0.15 (-5.44%)
Updated Aug 6, 2025 03:44 PM ET
2-Buy of 5 2
F Value F Growth B Momentum F VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
ADCT 2.61 -0.15(-5.44%)
Will ADCT be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for ADCT based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for ADCT
Are Medical Stocks Lagging ADC Therapeutics (ADCT) This Year?
ADC Therapeutics SA (ADCT) Reports Q1 Loss, Tops Revenue Estimates
ADCT: What are Zacks experts saying now?
Zacks Private Portfolio Services
Zymeworks Inc. (ZYME) Reports Q1 Loss, Tops Revenue Estimates
Kura Oncology (KURA) Reports Q1 Loss, Lags Revenue Estimates
AC Immune (ACIU) Reports Q1 Loss, Lags Revenue Estimates
Other News for ADCT
ADC Therapeutics to Host Second Quarter 2025 Financial Results Conference Call on August 12, ...
ADC Therapeutics Makes Grants to New Employees Under Inducement Plan | ADCT Stock News
ADC Therapeutics Makes Grant to New Employee Under Inducement Plan | ADCT Stock News
ADC Therapeutics (ADCT) Files Prospectus for Share Sale
ADC Therapeutics files to sell 27.73M common shares by selling shareholders